For 2023, ImmunoGen expects: Revenues, excluding product revenue from ELAHERE, between $30 million and $35 million; and operating expenses between $310 million and $320 million.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
Questions or Comments about the article? Write to editor@tipranks.com